This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutAboutAntibacterialsAntifungalsAntimicrobial Resistance(AMR)Our CommitmentOur CommitmentPfizer’s Heritage in AMR
About Antifungals

Antimicrobial medicines (antibiotics that target bacteria, antivirals that target viruses, and antifungals that target fungi) are among the most precious medical resources the world has ever known.1 Invasive fungal infections can pose a major threat to life and health worldwide, especially in immunocompromised patients.2 Pfizer offers a range of antifungal medicines to treat serious infections.3-6  Discover the heritage of our antifungal portfolio and learn more about invasive fungal infections and their management below.

Prescribing Information

Cresemba ® (isavuconazonium sulfate) 

 
Ecalta® (anidulafungin) 
 
Diflucan® (fluconazole) 
 
Vfend® (voriconazole) 

References:Review on Antimicrobial Resistance. Tackling a crisis for the health and wealth of nations. December 2014. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Last accessed January 2023. Centers for Disease Control and Prevention. (2021, August 26). Fungal Diseases. Retrieved September 2022, from https://www.cdc.gov/fungal/infections/index.htmlCRESEMBA. Summary of product characteristics. 2022. Ecalta. Summary of Product characteristics. 2021. Diflucan. Summary of Product Characteristics. 2022. VFEND. Summary of Product Characteristics. 2022.
About Anti-infectives Signs and symptoms

Clinical suspicion of haemophilia should be raised for patients with a history of easy bruising, spontaneous, or excessive bleeding following trauma or surgery.1

 Find out more Treatment options

Haemophilia management involves treating specific haemorrhages, as well as preventing bleed recurrence, limiting complications, and restoring tissue and/or organ function to a pre-bleed state.1​​​​​​​

 Find out more

Legal Category: S1A
Further information is available upon request

PP-UNP-IRL-0349 Date of preparation: January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.